ScreenerHero

MDWDMediWound Ltd.

NAS · US · Healthcare · Biotechnology · mediwound.com
13.21USDMkt Cap: 170.54M $P/E: —

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, a…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap170.54M $
Enterprise Value142.58M $
Revenue (TTM)11.86M $
Gross Profit3.25M $
Net Income (TTM)-23.88M $
Revenue/Share0.9570 USD
Last Price13.21 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees121
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.73
PEG—
EV/EBITDA-4.64
EV/Revenue12.02
P/S14.27
P/B4.08
EPS (TTM)-2.16
EPS (Forward)-2.29
52W Range
13.0657% of range13.32
52W High13.32 USD
52W Low13.06 USD
Profitability
Gross Margin19.19%
Oper. Margin-305.89%
EBITDA Margin-259.20%
Profit Margin-140.80%
ROE-54.73%
ROA-27.68%
Growth
Revenue Growth-45.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-16.12M $
CapEx (TTM)5.50M $
FCF Margin-244.87%
FCF Yield-17.03%
Net Debt-26.74M $
Net Debt/EBITDA0.87
Balance Sheet
Debt/Equity0.19
Current Ratio2.32
Quick Ratio2.09
Book Value/Sh3.218 USD
Cash/Share2.737 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:7
Split DateDec 20, 2022
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)29.83 USD
Upside (mean)+125.8%
Target Range22.00 USD – 36.00 USD
$22.00+125.8% to mean$36.00
# Analysts6
Ownership
Shares Out.12.91M
Float8.87M
Insiders15.96%
Institutions53.62%
Short Interest
Short Ratio22.2d
Short % Float14.34%
Short % Out.12.55%
Shares Short1.61M
Short (prev mo.)1.63M
Technical
SMA 5014.29 (-7.6%)
SMA 20016.56 (-20.2%)
Beta0.16
S&P 52W Chg21.00%
Avg Vol (30d)79.70K
Avg Vol (10d)55.36K
Technical Indicators
RSI (14)34.9
MACD-0.3065
MACD Signal-0.2370
MACD Hist.-0.0695
BB Upper14.81 USD
BB Middle13.94 USD
BB Lower13.07 USD
BB Width12.48%
ATR (14)0.4603 USD
Vol Ratio (20d)1.34x